Dr. Gabriel Hortobagyi on the Impact of MONALEESA-2 Trial in HR+ Breast Cancer

Gabriel N. Hortobagyi, MD
Published: Wednesday, Nov 09, 2016


Gabriel N. Hortobagyi, MD, professor of Medicine at the University of Texas MD Anderson Cancer Center, discusses the MONALEESA-2 trial, which has shown that the addition of ribociclib to letrozole significantly improved progression-free survival (PFS) in postmenopausal women with hormone receptor (HR)­-positive advanced breast cancer.  
 
Patients in the ribociclib arm had a 44% reduction in the risk of progression or death compared with patients who recieved placebo plus hormone therapy. This difference satisfied prespecified statistical requirements for superiority.
 
These findings are practice-changing, says Hortobagyi. Up until the development of the CDK4/6 inhibitors, the standard of care for managing patients with HR-positive metastatic breast cancer was an aromatase inhibitor such as letrozole or anastrozole. Based on these findings, going forward, the treatment of choice for these same postmenopausal women with HR-positive breast cancer will be a combination of a drug like letrozole with a CDK4/6 inhibitor such as ribociclib, he says.

This is a major change because with letrozole alone, the best data was about a 14-month PFS. With the addition of ribociclib, patients are expected to live significantly longer, says Hortobagyi.  

Gabriel N. Hortobagyi, MD, professor of Medicine at the University of Texas MD Anderson Cancer Center, discusses the MONALEESA-2 trial, which has shown that the addition of ribociclib to letrozole significantly improved progression-free survival (PFS) in postmenopausal women with hormone receptor (HR)­-positive advanced breast cancer.  
 
Patients in the ribociclib arm had a 44% reduction in the risk of progression or death compared with patients who recieved placebo plus hormone therapy. This difference satisfied prespecified statistical requirements for superiority.
 
These findings are practice-changing, says Hortobagyi. Up until the development of the CDK4/6 inhibitors, the standard of care for managing patients with HR-positive metastatic breast cancer was an aromatase inhibitor such as letrozole or anastrozole. Based on these findings, going forward, the treatment of choice for these same postmenopausal women with HR-positive breast cancer will be a combination of a drug like letrozole with a CDK4/6 inhibitor such as ribociclib, he says.

This is a major change because with letrozole alone, the best data was about a 14-month PFS. With the addition of ribociclib, patients are expected to live significantly longer, says Hortobagyi.  

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Publication Bottom Border
Border Publication
x